Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-09-26 pm EDT
9.970 USD   -7.60%
09/23Beyond The Deal : Recursion's Transformational Partnership with Roche and Genentech
PU
09/19Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to S&P Biotechnology Select Industry Index
CI
09/16KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company decoding biology by integrating technology across biology, chemistry, automation, machine learning, and engineering to industrialize drug discovery. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.
Sales per Business
20202021Delta
Biotechnology3.96100%10.18100% +156.89%
USD in Million
Sales per region
20202021Delta
United States3.96100%10.18100% +156.89%
USD in Million
Managers
Name Title Age Since
Chistopher Gibson Chief Executive Officer & Director 38 2013
Tina Larson Chief Operating Officer 46 2018
Michael Secora Chief Financial Officer 38 2020
Benjamin Mabey Vice President-Software Engineering 38 2017
Shafique Virani, Dr. Chief Medical & Business Officer 50 2022
Jordan Christensen Vice President-Engineering - 2021
Mason Victors Senior Data Scientist 34 2015
Glenn Morrison, Dr. Vice President-Clinical Development - 2021
Louisa Daniels Chief Legal Officer & General Counsel 63 2021
Heather Kirkby Chief People Officer 48 2019
Members of the board
Name Title Age Since
Ramon Chavez Independent Chairman 57 2021
Blake Borgeson Independent Director 39 2018
Dean Li Independent Director 59 -
Zavain Dar Independent Director 32 2016
Zachary Bogue Independent Director 45 2018
Robert M. Hershberg, Dr. Independent Director 57 2020
Terry-Ann Burrell Independent Director 44 2020
Chistopher Gibson Chief Executive Officer & Director 38 2013
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 173,076,691 152,282,313 88.0% 0 0.0% 84.1%
Stock B 10 7,957,209 0 0.0% 0 0.0%
Shareholders
NameEquities%
Baillie Gifford & Co. 21,605,685 13.1%
Mubadala Investment Co. (Private Equity) 15,803,786 9.57%
DCVC Management Co. LLC 13,619,224 8.25%
Lux Capital Group LLC 13,021,519 7.88%
MIC Capital Management UK LLP 8,451,758 5.12%
Blake Borgeson 7,671,777 4.65%
Bayer Aktiengesellschaft 7,453,926 4.51%
Steven Theodere Stull 7,422,358 4.49%
The Vanguard Group, Inc. 6,847,001 4.15%
Obvious Management Services LLC 5,977,631 3.62%
Company contact information
Recursion Pharmaceuticals, Inc.
41 South Rio Grande Street
Salt Lake City, UT 84101

Phone : +1.385.269.0203
Fax : +1.801.821.2872
Web : http://www.recursion.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Recursion Pharmaceuticals, Inc.
Connections : Recursion Pharmaceuticals, Inc.